AABB is conducting an optional and anonymous survey to collect information on how recent executive orders have affected AABB members and blood and biotherapies research. Our goal is to gather real-world examples that may be shared with members of Congress and the Administration. Please provide de-identified details about any specific ways these executive orders have influenced your work and research. Feel free to skip any questions you prefer not to answer.
Which programs, research, and/or practices will be most impacted by recent executive orders? Please be as specific as possible about how this will impact innovation in blood and biotherapies and ultimately affect patient care.
Please provide de-identified examples of actions your institution has taken in response to the new executive orders regarding the pause of communications, funding freeze, and the caps on facility and administration costs. Please be specific about how this has changed/could change your time in the lab, impact the research workforce, impact early career investigators, and impact patient care.
We want to highlight how breakthroughs in blood and biotherapies are prime examples of innovation in science. Please provide an example of how NIH-supported basic science research in blood and biotherapies has led to innovation and breakthroughs in medical research (e.g., pathogen reduction, monoclonal antibodies, gene therapy, CAR-T therapy, mRNA, others).
What questions would you like us to share with Congress?
If you are willing to provide AABB staff with additional follow-up details, feel free to email us at advocacy@aabb.org or share your name and email below. This information will be kept confidential.
